



April 08, 2022

|   |  |
|---|--|
| To<br>The Manager<br>Listing Department<br><b>National Stock Exchange of India Limited</b><br>'Exchange Plaza', C - 1, Block G,<br>Bandra-Kurla Complex,<br><u>Bandra (E), Mumbai 400051.</u><br>Scrip Code: INDOCO | To<br><b>BSE Limited</b><br>Corporate Relationship<br>Department<br>1 <sup>st</sup> Floor, New Trading Ring,<br>Phiroze Jeejeebhoy Towers<br>Dalal Street<br><u>Mumbai 400001</u><br>Scrip Code : 532612 |
|---|--|

Dear Sirs,

**Sub: Disclosure under Regulation 30 of LODR Regulations 2015**

**Indoco Remedies receives USFDA approval for Lacosamide Injection USP**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find Press Release for your information and record.

**For Indoco Remedies Limited**

**Jayshankar Menon**  
AVP (Legal) & Company Secretary





## PRESS RELEASE

### **Indoco Remedies receives USFDA approval for Lacosamide Injection USP**

**Mumbai, April 8, 2022:** Indoco Remedies Ltd. today announced that the United States Food & Drug Administration (USFDA) has approved the ANDA Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL) single-dose vials. The generic Lacosamide Injection USP of Indoco Remedies is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vimpat® Injection of UCB, Inc.

Lacosamide injection is indicated for the prevention and control of seizures. It is an anticonvulsant / antiepileptic drug.

Commenting on the development, **Ms. Aditi Kare Panandikar, Managing Director-Indoco Remedies** said, "Lacosamide Injection of Indoco is the first generic version of Vimpat® Injection of UCB Inc., approved in the United States. The ANDA approval and immediate launch of the product in the US market, echoes our commitment and consistent efforts to meet the unmet needs of the patients with quality and affordable healthcare.

According to available IQVIA, sales data for Vimpat® Injection is approx. USD 43.8 million, growing at 25%.

#### **About Indoco Remedies Ltd**

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 166 million Company, employs over 6000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritional, Cardiovascular, Anti-Diabetics, Pain Management, Gyneacology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensiform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

#### **For Media Inquiries Please Contact:**

**Vilas V. Nagare**

Mobile: 9820215745

E-mail: [vilasn@indoco.com](mailto:vilasn@indoco.com) / [corpcom@indoco.com](mailto:corpcom@indoco.com)